If a drug deemed ‘safe’ in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?
New drugs are now routinely investigated for their QT-liability in nonclinical studies as well as in a formal Thorough QT Study in man. Data from these studies in man have provided better evidence of the benefits of defining concentration-QT effect relationship of a drug. Therefore, sponsors also fr...
Saved in:
| Published in | Pharmacology & therapeutics (Oxford) Vol. 119; no. 2; pp. 215 - 221 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
England
01.08.2008
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0163-7258 |
| DOI | 10.1016/j.pharmthera.2008.03.002 |
Cover
| Abstract | New drugs are now routinely investigated for their QT-liability in nonclinical studies as well as in a formal Thorough QT Study in man. Data from these studies in man have provided better evidence of the benefits of defining concentration-QT effect relationship of a drug. Therefore, sponsors also frequently monitor electrocardiograms in early phase I clinical pharmacology studies. Although very rare, it is not inconceivable that a drug deemed safe in nonclinical studies may be found to have QT-liability in these early phase clinical studies. Regulatory authorities will no doubt seek a scientific explanation for this discrepancy and as long as the safety of subjects in later phase clinical trials is assured, are content to let the sponsor decide whether to continue or terminate the development of such drugs. Nevertheless, regulatory authorities are prepared provide advice at all the key stages on the optimal way forward so that regulatory concerns likely to arise at evaluation are addressed ahead of submission. Regulatory approval of a drug with QT-liability depends on the comparison of its overall risk/benefit analysis with alternatives available and the morbidity and mortality associated with the disease to be treated. Recent high profile withdrawal of drugs provides a clear signal that cardiac safety is high on the regulatory agenda. An additional regulatory concern is that although QT-related risk can be communicated by appropriate labeling, this may not be enough to mitigate the proarrhythmic risk in clinical practice. A major challenge is to ensure that such drugs are used appropriately. |
|---|---|
| AbstractList | New drugs are now routinely investigated for their QT-liability in nonclinical studies as well as in a formal Thorough QT Study in man. Data from these studies in man have provided better evidence of the benefits of defining concentration-QT effect relationship of a drug. Therefore, sponsors also frequently monitor electrocardiograms in early phase I clinical pharmacology studies. Although very rare, it is not inconceivable that a drug deemed safe in nonclinical studies may be found to have QT-liability in these early phase clinical studies. Regulatory authorities will no doubt seek a scientific explanation for this discrepancy and as long as the safety of subjects in later phase clinical trials is assured, are content to let the sponsor decide whether to continue or terminate the development of such drugs. Nevertheless, regulatory authorities are prepared provide advice at all the key stages on the optimal way forward so that regulatory concerns likely to arise at evaluation are addressed ahead of submission. Regulatory approval of a drug with QT-liability depends on the comparison of its overall risk/benefit analysis with alternatives available and the morbidity and mortality associated with the disease to be treated. Recent high profile withdrawal of drugs provides a clear signal that cardiac safety is high on the regulatory agenda. An additional regulatory concern is that although QT-related risk can be communicated by appropriate labeling, this may not be enough to mitigate the proarrhythmic risk in clinical practice. A major challenge is to ensure that such drugs are used appropriately. New drugs are now routinely investigated for their QT-liability in nonclinical studies as well as in a formal Thorough QT Study in man. Data from these studies in man have provided better evidence of the benefits of defining concentration-QT effect relationship of a drug. Therefore, sponsors also frequently monitor electrocardiograms in early phase I clinical pharmacology studies. Although very rare, it is not inconceivable that a drug deemed safe in nonclinical studies may be found to have QT-liability in these early phase clinical studies. Regulatory authorities will no doubt seek a scientific explanation for this discrepancy and as long as the safety of subjects in later phase clinical trials is assured, are content to let the sponsor decide whether to continue or terminate the development of such drugs. Nevertheless, regulatory authorities are prepared provide advice at all the key stages on the optimal way forward so that regulatory concerns likely to arise at evaluation are addressed ahead of submission. Regulatory approval of a drug with QT-liability depends on the comparison of its overall risk/benefit analysis with alternatives available and the morbidity and mortality associated with the disease to be treated. Recent high profile withdrawal of drugs provides a clear signal that cardiac safety is high on the regulatory agenda. An additional regulatory concern is that although QT-related risk can be communicated by appropriate labeling, this may not be enough to mitigate the proarrhythmic risk in clinical practice. A major challenge is to ensure that such drugs are used appropriately.New drugs are now routinely investigated for their QT-liability in nonclinical studies as well as in a formal Thorough QT Study in man. Data from these studies in man have provided better evidence of the benefits of defining concentration-QT effect relationship of a drug. Therefore, sponsors also frequently monitor electrocardiograms in early phase I clinical pharmacology studies. Although very rare, it is not inconceivable that a drug deemed safe in nonclinical studies may be found to have QT-liability in these early phase clinical studies. Regulatory authorities will no doubt seek a scientific explanation for this discrepancy and as long as the safety of subjects in later phase clinical trials is assured, are content to let the sponsor decide whether to continue or terminate the development of such drugs. Nevertheless, regulatory authorities are prepared provide advice at all the key stages on the optimal way forward so that regulatory concerns likely to arise at evaluation are addressed ahead of submission. Regulatory approval of a drug with QT-liability depends on the comparison of its overall risk/benefit analysis with alternatives available and the morbidity and mortality associated with the disease to be treated. Recent high profile withdrawal of drugs provides a clear signal that cardiac safety is high on the regulatory agenda. An additional regulatory concern is that although QT-related risk can be communicated by appropriate labeling, this may not be enough to mitigate the proarrhythmic risk in clinical practice. A major challenge is to ensure that such drugs are used appropriately. |
| Author | Shah, Rashmi R. |
| Author_xml | – sequence: 1 givenname: Rashmi R. surname: Shah fullname: Shah, Rashmi R. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18455801$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkU1uFDEQhb0IIj9wBVQrVkxjt7s9ng0IRfxEioSQwtpy29UzHrntwXYnyi7HgAtwsJwEtxJAYsPKkv3Ve-X3TslRiAEJAUYbRpl4vW8OO52mssOkm5ZS2VDeUNoekZP6zFfrtpfH5DTnPaW062j7lBwz2fW9pOyE_LwYQYNN8xYs4oQW7u--Zz3i_d0PcAGqmfEuOKM9FMwlQ56HjN9mDMXfwiFFH8M2w5erha6bZAQGuczWYX4Fu3gDRgdwy-AhhhwTmBiuXTAICbez1yWmDCWC9r7CFq_Rx8NU5ZfLqm8Q7dtn5Mmofcbnj-cZ-frh_dX5p9Xl548X5-8uV4YzXlbCbtZcUqEZp6ZnPZVa94aOYmPbQXDLxMhs27WyH6SQIx8E4yi6GlPLR7QjPyMvH3Srcf1jLmpy2aD3OmCcsxKbTvZr0VfwxSM4DzU1dUhu0ulW_U62Am8eAJNizglHZVzRxcVQknZeMaqW-tRe_a1PLfUpylWtrwrIfwT-ePxv9BcBl6sB |
| CitedBy_id | crossref_primary_10_1111_j_1440_1681_2010_05349_x crossref_primary_10_1007_BF03261967 crossref_primary_10_1211_jpp_62_01_0008 crossref_primary_10_1111_j_1476_5381_2009_00427_x crossref_primary_10_1016_j_pharmthera_2008_05_004 crossref_primary_10_1016_j_pcad_2010_05_005 crossref_primary_10_1016_j_vascn_2010_06_005 crossref_primary_10_2165_11535230_000000000_00000 crossref_primary_10_1016_j_pharmthera_2009_10_002 crossref_primary_10_1007_s11096_024_01703_3 crossref_primary_10_1038_bjp_2008_280 |
| Cites_doi | 10.1046/j.1365-2125.2002.01627.x 10.1056/NEJMoa062222 10.2165/00002018-200730120-00003 10.1038/sj.bjp.0706892 10.1517/14740338.4.1.103 10.1097/01.md.0000085057.63483.9b 10.1136/bmj.283.6296.881 10.2165/00002018-200629070-00003 10.1056/NEJMoa054830 10.2165/00002018-200427030-00001 10.1016/S0002-9343(02)01455-9 10.1001/jama.294.20.joc50147 10.1517/14728222.11.3.321 10.1097/00005344-200301000-00018 10.1042/BST0351060 10.1016/0140-6736(92)90129-Q 10.1111/j.1365-2125.1982.tb02022.x 10.1056/NEJMoa050493 10.1046/j.1472-8206.2002.00083.x 10.1016/j.cardiores.2007.06.019 10.2133/dmpk.19.83 10.1097/00004714-200304000-00013 10.1001/jama.284.23.3036 10.1177/0091270007307881 10.1038/sj.bjp.0707537 10.1067/mcp.2000.105761 10.1016/j.vascn.2005.03.008 10.4065/78.12.1479 10.1001/jama.270.21.2590 10.1517/14622416.5.7.895 10.1111/j.1365-2125.2006.02793.x |
| ContentType | Journal Article |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.pharmthera.2008.03.002 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EndPage | 221 |
| ExternalDocumentID | 18455801 10_1016_j_pharmthera_2008_03_002 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .GJ .~1 0R~ 123 1B1 1RT 1~. 1~5 29O 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO AAYXX ABFNM ABMAC ABWVN ABXDB ABZDS ACDAQ ACGFO ACIUM ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AFFNX AFJKZ AFPUW AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CITATION CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IHE J1W K-O KOM L7B M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SCC SDF SDG SDP SES SEW SPCBC SPT SSP SSZ T5K TEORI WUQ Y6R ZGI ZXP ~G- ~HD AACTN BNPGV CGR CUY CVF ECM EIF NPM RIG SSH 7X8 |
| ID | FETCH-LOGICAL-c313t-6d973806a130c51508aa5c0f69d2b63d16f1d24285b868f3b613e6416323fedf3 |
| ISSN | 0163-7258 |
| IngestDate | Sat Sep 27 18:06:16 EDT 2025 Thu Apr 03 07:06:24 EDT 2025 Wed Oct 01 03:48:41 EDT 2025 Thu Apr 24 23:07:12 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c313t-6d973806a130c51508aa5c0f69d2b63d16f1d24285b868f3b613e6416323fedf3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 18455801 |
| PQID | 69485765 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_69485765 pubmed_primary_18455801 crossref_citationtrail_10_1016_j_pharmthera_2008_03_002 crossref_primary_10_1016_j_pharmthera_2008_03_002 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2008-8-00 2008-Aug 20080801 |
| PublicationDateYYYYMMDD | 2008-08-01 |
| PublicationDate_xml | – month: 08 year: 2008 text: 2008-8-00 |
| PublicationDecade | 2000 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Pharmacology & therapeutics (Oxford) |
| PublicationTitleAlternate | Pharmacol Ther |
| PublicationYear | 2008 |
| References | Slørdal (10.1016/j.pharmthera.2008.03.002_bib34) 2006; 29 Food and Drug Administration (10.1016/j.pharmthera.2008.03.002_bib11) 2007 Ozawa (10.1016/j.pharmthera.2008.03.002_bib21) 2004; 19 Committee for Medicinal Products for Human Use (10.1016/j.pharmthera.2008.03.002_bib6) 2005 Makkar (10.1016/j.pharmthera.2008.03.002_bib18) 1993; 270 Roche (10.1016/j.pharmthera.2008.03.002_bib23) 1992; 339 Benton (10.1016/j.pharmthera.2008.03.002_bib2) 2000; 67 Curtis (10.1016/j.pharmthera.2008.03.002_bib7) 2003; 114 Committee for Medicinal Products for Human Use (10.1016/j.pharmthera.2008.03.002_bib5) 2005 Shah (10.1016/j.pharmthera.2008.03.002_bib30) 2005; 4 Bresalier (10.1016/j.pharmthera.2008.03.002_bib4) 2005; 352 Schade (10.1016/j.pharmthera.2008.03.002_bib25) 2007; 356 Health Canada (10.1016/j.pharmthera.2008.03.002_bib17) 2006 Douglas (10.1016/j.pharmthera.2008.03.002_bib9) 1981; 283 Wible (10.1016/j.pharmthera.2008.03.002_bib40) 2005; 52 Bowen (10.1016/j.pharmthera.2008.03.002_bib3) 1997; 46 Shah (10.1016/j.pharmthera.2008.03.002_bib28) 2004; 27 Food and Drug Administration (10.1016/j.pharmthera.2008.03.002_bib10) 2005 Shah (10.1016/j.pharmthera.2008.03.002_bib32) 2007; 30 Zeltser (10.1016/j.pharmthera.2008.03.002_bib43) 2003; 82 Dennis (10.1016/j.pharmthera.2008.03.002_bib8) 2007; 35 Gallacher (10.1016/j.pharmthera.2008.03.002_bib13) 2007; 76 Olatunde (10.1016/j.pharmthera.2008.03.002_bib20) 1982; 14 Solus (10.1016/j.pharmthera.2008.03.002_bib36) 2004; 5 Ackerman (10.1016/j.pharmthera.2008.03.002_bib1) 2003; 78 Shah (10.1016/j.pharmthera.2008.03.002_bib31) 2007 Food and Drug Administration (10.1016/j.pharmthera.2008.03.002_bib12) 2007 Temple (10.1016/j.pharmthera.2008.03.002_bib38) 2003 Health Canada (10.1016/j.pharmthera.2008.03.002_bib15) 2006 Rajamani (10.1016/j.pharmthera.2008.03.002_bib22) 2006; 149 Shah (10.1016/j.pharmthera.2008.03.002_bib26) 2002; 54 Shin (10.1016/j.pharmthera.2008.03.002_bib33) 2006; 63 Smalley (10.1016/j.pharmthera.2008.03.002_bib35) 2000; 284 Zanettini (10.1016/j.pharmthera.2008.03.002_bib42) 2007; 356 Takemasa (10.1016/j.pharmthera.2008.03.002_bib37) 2008; 153 Roe (10.1016/j.pharmthera.2008.03.002_bib24) 2003; 23 Health Canada (10.1016/j.pharmthera.2008.03.002_bib16) 2006 Garnett (10.1016/j.pharmthera.2008.03.002_bib14) 2008; 48 Nissen (10.1016/j.pharmthera.2008.03.002_bib19) 2005; 294 Witchel (10.1016/j.pharmthera.2008.03.002_bib41) 2007; 11 Shah (10.1016/j.pharmthera.2008.03.002_bib27) 2002; 16 Shah (10.1016/j.pharmthera.2008.03.002_bib29) 2005 Thomas (10.1016/j.pharmthera.2008.03.002_bib39) 2003; 41 |
| References_xml | – volume: 46 start-page: 1061 year: 1997 ident: 10.1016/j.pharmthera.2008.03.002_bib3 article-title: Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine. US Department of Health and Human Services Interim Public Health Recommendations publication-title: MMWR Morb Mortal Wkly Rep – volume: 54 start-page: 188 year: 2002 ident: 10.1016/j.pharmthera.2008.03.002_bib26 article-title: The significance of QT interval in drug development publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.2002.01627.x – year: 2005 ident: 10.1016/j.pharmthera.2008.03.002_bib10 – volume: 356 start-page: 29 year: 2007 ident: 10.1016/j.pharmthera.2008.03.002_bib25 article-title: Dopamine agonists and the risk of cardiac-valve regurgitation publication-title: N Engl J Med doi: 10.1056/NEJMoa062222 – year: 2006 ident: 10.1016/j.pharmthera.2008.03.002_bib17 article-title: Question and answer document regarding the ICH S7B and E14 guidances – volume: 30 start-page: 1093 year: 2007 ident: 10.1016/j.pharmthera.2008.03.002_bib32 article-title: Cardiac repolarization and drug regulation: assessing cardiac safety 10 years after the CPMP guidance publication-title: Drug Safety doi: 10.2165/00002018-200730120-00003 – volume: 149 start-page: 481 year: 2006 ident: 10.1016/j.pharmthera.2008.03.002_bib22 article-title: Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0706892 – volume: 4 start-page: 103 year: 2005 ident: 10.1016/j.pharmthera.2008.03.002_bib30 article-title: Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules publication-title: Expert Opin Drug Saf doi: 10.1517/14740338.4.1.103 – volume: 82 start-page: 282 year: 2003 ident: 10.1016/j.pharmthera.2008.03.002_bib43 article-title: Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors publication-title: Medicine (Baltimore) doi: 10.1097/01.md.0000085057.63483.9b – start-page: 251 year: 2005 ident: 10.1016/j.pharmthera.2008.03.002_bib29 article-title: Drug-induced QT interval prolongation: regulatory guidance and perspectives on hERG channel studies – volume: 283 start-page: 881 year: 1981 ident: 10.1016/j.pharmthera.2008.03.002_bib9 article-title: Pulmonary hypertension and fenfluramine publication-title: BMJ doi: 10.1136/bmj.283.6296.881 – volume: 29 start-page: 567 year: 2006 ident: 10.1016/j.pharmthera.2008.03.002_bib34 article-title: Heart failure induced by non-cardiac drugs publication-title: Drug Safety doi: 10.2165/00002018-200629070-00003 – volume: 356 start-page: 39 year: 2007 ident: 10.1016/j.pharmthera.2008.03.002_bib42 article-title: Valvular heart disease and the use of dopamine agonists for Parkinson's disease publication-title: N Engl J Med doi: 10.1056/NEJMoa054830 – volume: 27 start-page: 145 year: 2004 ident: 10.1016/j.pharmthera.2008.03.002_bib28 article-title: Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing publication-title: Drug Safety doi: 10.2165/00002018-200427030-00001 – volume: 114 start-page: 135 year: 2003 ident: 10.1016/j.pharmthera.2008.03.002_bib7 article-title: Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients publication-title: Am J Med doi: 10.1016/S0002-9343(02)01455-9 – year: 2007 ident: 10.1016/j.pharmthera.2008.03.002_bib12 – year: 2005 ident: 10.1016/j.pharmthera.2008.03.002_bib6 – volume: 294 start-page: 2581 year: 2005 ident: 10.1016/j.pharmthera.2008.03.002_bib19 article-title: Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus publication-title: JAMA doi: 10.1001/jama.294.20.joc50147 – volume: 11 start-page: 321 year: 2007 ident: 10.1016/j.pharmthera.2008.03.002_bib41 article-title: The hERG potassium channel as a therapeutic target publication-title: Expert Opin Ther Targets doi: 10.1517/14728222.11.3.321 – year: 2007 ident: 10.1016/j.pharmthera.2008.03.002_bib11 – volume: 41 start-page: 140 year: 2003 ident: 10.1016/j.pharmthera.2008.03.002_bib39 article-title: HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current publication-title: J Cardiovasc Pharmacol doi: 10.1097/00005344-200301000-00018 – volume: 35 start-page: 1060 year: 2007 ident: 10.1016/j.pharmthera.2008.03.002_bib8 article-title: hERG channel trafficking: novel targets in drug-induced long QT syndrome publication-title: Biochem Soc Trans doi: 10.1042/BST0351060 – volume: 339 start-page: 436 year: 1992 ident: 10.1016/j.pharmthera.2008.03.002_bib23 article-title: Pulmonary hypertension and dexfenfluramine publication-title: Lancet doi: 10.1016/0140-6736(92)90129-Q – year: 2003 ident: 10.1016/j.pharmthera.2008.03.002_bib38 article-title: Premarketing risk assessment: special conditions – volume: 14 start-page: 513 year: 1982 ident: 10.1016/j.pharmthera.2008.03.002_bib20 article-title: Blood quinidine levels and cardiac effects in white British and Nigerian subjects publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1982.tb02022.x – volume: 352 start-page: 1092 year: 2005 ident: 10.1016/j.pharmthera.2008.03.002_bib4 article-title: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial publication-title: N Engl J Med doi: 10.1056/NEJMoa050493 – year: 2006 ident: 10.1016/j.pharmthera.2008.03.002_bib15 article-title: Guide for the analysis and review of QT/QTc interval data – volume: 16 start-page: 147 year: 2002 ident: 10.1016/j.pharmthera.2008.03.002_bib27 article-title: Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labeling of a new chemical entity publication-title: Fundam Clin Pharmacol doi: 10.1046/j.1472-8206.2002.00083.x – volume: 76 start-page: 247 year: 2007 ident: 10.1016/j.pharmthera.2008.03.002_bib13 article-title: In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome publication-title: Cardiovasc Res doi: 10.1016/j.cardiores.2007.06.019 – volume: 19 start-page: 83 year: 2004 ident: 10.1016/j.pharmthera.2008.03.002_bib21 article-title: Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1 publication-title: Drug Metab Pharmacokin doi: 10.2133/dmpk.19.83 – volume: 23 start-page: 197 year: 2003 ident: 10.1016/j.pharmthera.2008.03.002_bib24 article-title: Concomitant use of antipsychotics and drugs that may prolong the QT interval publication-title: J Clin Psychopharmacol doi: 10.1097/00004714-200304000-00013 – year: 2005 ident: 10.1016/j.pharmthera.2008.03.002_bib5 – volume: 284 start-page: 3036 year: 2000 ident: 10.1016/j.pharmthera.2008.03.002_bib35 article-title: Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action publication-title: JAMA doi: 10.1001/jama.284.23.3036 – volume: 48 start-page: 13 year: 2008 ident: 10.1016/j.pharmthera.2008.03.002_bib14 article-title: Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review publication-title: J Clin Pharmacol doi: 10.1177/0091270007307881 – volume: 153 start-page: 439 year: 2008 ident: 10.1016/j.pharmthera.2008.03.002_bib37 article-title: Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0707537 – volume: 67 start-page: 413 year: 2000 ident: 10.1016/j.pharmthera.2008.03.002_bib2 article-title: Greater quinidine-induced QTc interval prolongation in women publication-title: Clin Pharmacol Ther doi: 10.1067/mcp.2000.105761 – year: 2006 ident: 10.1016/j.pharmthera.2008.03.002_bib16 article-title: QT/QTc interval prolongation: guidance for product monograph content – volume: 52 start-page: 136 year: 2005 ident: 10.1016/j.pharmthera.2008.03.002_bib40 article-title: HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk publication-title: J Pharmacol Toxicol Methods doi: 10.1016/j.vascn.2005.03.008 – volume: 78 start-page: 1479 year: 2003 ident: 10.1016/j.pharmthera.2008.03.002_bib1 article-title: Ethnic differences in cardiac potassium channel variants: Implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome publication-title: Mayo Clin Proc doi: 10.4065/78.12.1479 – start-page: 180 year: 2007 ident: 10.1016/j.pharmthera.2008.03.002_bib31 article-title: Pharmacogenetics, ethnic differences in drug response and drug regulation – volume: 270 start-page: 2590 year: 1993 ident: 10.1016/j.pharmthera.2008.03.002_bib18 article-title: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs publication-title: JAMA doi: 10.1001/jama.270.21.2590 – volume: 5 start-page: 895 year: 2004 ident: 10.1016/j.pharmthera.2008.03.002_bib36 article-title: Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population publication-title: Pharmacogenomics doi: 10.1517/14622416.5.7.895 – volume: 63 start-page: 206 year: 2006 ident: 10.1016/j.pharmthera.2008.03.002_bib33 article-title: Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2006.02793.x |
| SSID | ssj0004402 |
| Score | 1.9781873 |
| SecondaryResourceType | review_article |
| Snippet | New drugs are now routinely investigated for their QT-liability in nonclinical studies as well as in a formal Thorough QT Study in man. Data from these studies... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 215 |
| SubjectTerms | Clinical Trials, Phase I as Topic Drug Approval Drug Design Drugs, Investigational - adverse effects Electrocardiography Government Agencies - legislation & jurisprudence Humans Long QT Syndrome - chemically induced Risk Assessment - methods |
| Title | If a drug deemed ‘safe’ in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed? |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/18455801 https://www.proquest.com/docview/69485765 |
| Volume | 119 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier ScienceDirect issn: 0163-7258 databaseCode: .~1 dateStart: 19950101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.sciencedirect.com omitProxy: true ssIdentifier: ssj0004402 providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] issn: 0163-7258 databaseCode: ACRLP dateStart: 19950101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.sciencedirect.com omitProxy: true ssIdentifier: ssj0004402 providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] issn: 0163-7258 databaseCode: AIKHN dateStart: 19950101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.sciencedirect.com omitProxy: true ssIdentifier: ssj0004402 providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals issn: 0163-7258 databaseCode: AKRWK dateStart: 19930101 customDbUrl: isFulltext: true mediaType: online dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004402 providerName: Library Specific Holdings |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKcuGCeFOec4DdQ5uqedhNTwjBrnbRsrCQSr1FTuLQrKAtbaoVHOC_8EuZsZ0HqIiFS1RZdZro-zqeGX-eYexJiMCGnpIYlqD7FiR56sgRV07Gx0K5XKZK7-i-PhGHk-DVlE87ne8t1dKmTAbp163nSv4HVRxDXOmU7D8gW98UB_Az4otXRBivF8L4iM42ZqvNh16mFC5rPcq-y1yRMKKY9zCyrw8-okdZrntrNBNaO11SUmOFho-adp5GWks-wwWt5-qCs4UxHrPFOanC9OaCltIuVlqmXpA1WJku9tSsB_1X2r8_r45gaYEBDtrV8Tfx4NumWraR67TOgOkcsDnE2MpRvJ9Jnf15J9ezT4XVOFapirAWytXZS-E7I8_Uaq_NrzWZRSsMrowp32rkTb7hbLCkx9WPaDWxVKzWaxa2ajP_5E18MDk-jqP9aYRvtfzsUNMx2px_6r80rLjELnu4LFDvj8G3RiMUBFq0Wj-3lYIZgeD2n__Vv_lD0KKdl-gau2qjDnhuKHSdddT8Btu1QHzpQ9RCoA-70IboJvtxlIME4hkYnsEesWwPijm0OAaaY9DmGFQcg9OIvq05Bi5YjvUBGQbIMChoomEYVAyDhmFQLkAzDFoMo0HLsGe32ORgP3px6NjeHk7qu37piGw88sOhkOhDpZyaEkjJ02EuxpmXCD9zRe5m6D6GPAlFmPsJup1KUPTg-bnKcv8228E3VHcZ8FSmCbWlHGUikF4iM4q60RWVGIxnQ9FlowqROLWF76n_yse4UjiexQ2Wti-rHyOWXebWM5em-MsF5jyuQI_RUtP2m5yrxWYdCyrENBK8y-4YLjT3DAPO0VW899e599mV5o_1gO2Uq416iF5xmTzSzP0JsTm_Zg |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=If+a+drug+deemed+%27safe%27+in+nonclinical+tests+subsequently+prolongs+QT+in+phase+1+studies%2C+how+can+its+sponsor+convince+regulators+to+allow+development+to+proceed%3F&rft.jtitle=Pharmacology+%26+therapeutics+%28Oxford%29&rft.au=Shah%2C+Rashmi+R&rft.date=2008-08-01&rft.issn=0163-7258&rft.volume=119&rft.issue=2&rft.spage=215&rft_id=info:doi/10.1016%2Fj.pharmthera.2008.03.002&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0163-7258&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0163-7258&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0163-7258&client=summon |